Good technology. Real-world ready.

Acta Labs is an independent advisory and product lab helping health technology teams, funders and public-benefit organizations bring diagnostics and detection technologies into real-world use.

Advisory

Acta Labs works with diagnostics and health technology companies, funders and public-benefit organizations at the point where a promising technology has to become something people use, trust and pay for.

Engagements typically include

  • Assessing use cases and where a technology fits into clinical and public health workflows
  • Shaping product and evidence plans
  • Building the partnerships and business models that support adoption

Current focus

Diagnostics and detection for pandemic preparedness:

  • Point-of-care and distributed testing
  • Sample preparation and new platform technologies
  • Clinical metagenomics, where diagnosis meets surveillance
  • Patient safety in diagnostic pathways

Approach

Every engagement starts with three questions: what a technology needs to enable, who will use it, and where it fits into their work. Acta Labs uses three working tools to turn the answers into product requirements, development plans and evidence for adoption.

Exploration

Alongside advisory work, Acta Labs develops early concepts to test where new products could close real gaps. They're shared to invite conversation, collaborators and potential cofounders.

Exploratory concept

TriAct

Open, connected testing for routine respiratory care and emerging threats.

A proposed low-cost reader and software platform bringing host-response testing, compatible rapid pathogen tests and decision support into frontline care. The first application being assessed is nasal host-response testing for respiratory illness.

Exploratory concept

ReadySeq

Automated sample preparation for broad viral surveillance.

Beginning with municipal wastewater, ReadySeq aims to make sample preparation faster, simpler and less expensive by integrating processing and quality controls into a more consistent, automated workflow for downstream sequencing.

Software prototype

ActOnDx

Making sure serious diagnostic results lead to action.

ActOnDx helps care teams manage follow-up after a positive high-risk diagnostic result: coordinating next steps, tracking follow-up over time, keeping patients informed, and documenting resolution so fewer patients fall through the cracks.

Acta Labs welcomes development partnerships with healthcare teams, researchers, technology developers and funders interested in these directions, as well as potential cofounders with complementary scientific, clinical or technical expertise.

About

Portrait of Anastasia Liapis, PhD, founder of Acta Labs

Anastasia Liapis, PhD

Founder, Acta Labs

Anastasia works on getting diagnostics out of the lab and into real-world use, and on how tests in clinics and in the field can also give early warning of new outbreaks. She is a geneticist by training (PhD, Icahn School of Medicine at Mount Sinai), with postdoctoral work in immunology at NYU.

At GNA Biosolutions, she was part of the leadership team that took an ultrafast point-of-care molecular diagnostics platform from early development through emergency authorization during COVID-19 and acquisition by HP Inc. She then helped establish and lead HP Health Solutions, a health technology incubation business spanning diagnostics, digital health and pandemic preparedness.

Through Acta Labs, she now advises on and develops diagnostics and detection technologies for pandemic preparedness, from point-of-care and distributed testing to sample preparation, new platform technologies and clinical metagenomics. She was previously an Entrepreneur in Residence at Ambitious Impact through its Founding to Give program, run in partnership with the School for Moral Ambition, and was supported by Catalyze Impact in developing her work in pandemic preparedness.

Contact

Let's talk about an advisory engagement, a collaboration, or one of the ideas in development.